Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy : additional analyses from the AFFIRM randomized clinical trial

Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial D. Cella1*, C. Ivanescu2, S. Holmstrom3, C. N. Bui4, J. Spalding4 & K. Fizazi5 Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, USA; Consulting, Quintiles, Hoofddorp; Global Data Science, Health Economics & Outcomes Research, Astellas Pharma Global Development, Leiden, The Netherlands; Health Economics & Clinical Outcomes Research, Astellas Pharma US, Inc., Northbrook, USA; Institut Gustave Roussy, University of Paris Sud, Villejuif, France

[1]  Robert O'Neill,et al.  MMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA Datasets , 2009, Journal of biopharmaceutical statistics.

[2]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[3]  D. Eton,et al.  Combining Distribution- and Anchor-Based Approaches to Determine Minimally Important Differences , 2005, Evaluation & the health professions.

[4]  D. Cella,et al.  Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening , 2002, Quality of Life Research.

[5]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[6]  L. Hunt,et al.  Missing Data in Clinical Studies , 2007 .

[7]  David Cella,et al.  Brief assessment of priority symptoms in hormone refractory prostate cancer: The FACT Advanced Prostate Symptom Index (FAPSI) , 2003, Health and quality of life outcomes.

[8]  Bohdana Ratitch,et al.  Missing data in clinical trials: from clinical assumptions to statistical analysis using pattern mixture models , 2013, Pharmaceutical statistics.

[9]  E. Basch,et al.  Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[10]  D. Osoba,et al.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D Feuer,et al.  Prostate cancer: palliative care and pain relief , 2004, Prostate Cancer and Prostatic Diseases.

[12]  J. Holland,et al.  The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  J. Nelson,et al.  Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  Geert Molenberghs,et al.  Assessing and interpreting treatment effects in longitudinal clinical trials with missing data , 2003, Biological Psychiatry.

[15]  K. Pienta,et al.  Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. , 1997, Urology.

[16]  E. Basch.  Toward patient-centered drug development in oncology. , 2013, The New England journal of medicine.

[17]  E. Basch,et al.  Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. , 2014, The Lancet. Oncology.

[18]  G. Pond,et al.  Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study , 2008, Clinical Cancer Research.

[19]  Ohidul Siddiqui,et al.  MMRM versus MI in Dealing with Missing Data—A Comparison Based on 25 NDA Data Sets , 2011, Journal of biopharmaceutical statistics.